BeaconEquity.com announces an investment report featuring Antigenics Inc. (Nasdaq:AGEN). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/AGEN
Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/BeaconEquity
Antigenics Inc. (AGEN) is a biotechnology company developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Oncophage has been tested in phase III clinical trials for the treatment of renal cell carcinoma, a common type of kidney cancer, and for the treatment of metastatic melanoma. It has also been tested in phase I and phase II clinical trials in a range of indications and is in phase II clinical trials in glioma, a type of brain cancer.
Message Board Search for AGEN: http://www.boardcentral.com/boards/AGEN
In the report, the analyst notes:
“AGEN recently reported its results for the quarter and year ended December 31, 2009. The Company reported net income attributable to common stockholders of $1.7 million, or $0.02 per share, basic and diluted, for the fourth quarter of 2009, compared with net income attributable to common stockholders in the fourth quarter of 2008 of $3.9 million, or $0.06 per share, basic and diluted.
“The Company’s net cash burn (cash used in operating activities plus capital expenditures and dividend payments) for the years ended December 31, 2009, and 2008, was $25.2 million and $29.9 million, respectively. The 2009 net cash burn primarily reflects the Company’s efforts to support Oncophage® (vitespen), the Company’s novel patient-specific cancer vaccine, in Russia, Europe and other territories, while also executing cost containment efforts.”
SOURCE Beacon Equity Research